Literature DB >> 28879784

Non-chemotherapy drug-induced neutropenia - an update.

Emmanuel Andrès1,2, Rachel Mourot-Cottet1,2.   

Abstract

INTRODUCTION: To date, non-chemotherapy drug-induced severe neutropenia (neutrophil count of ≤0.5 x 109/L) also called idiosyncratic drug-induced agranulocytosis is little discussed in the literature. In the present paper, we report and discuss the clinical data and management of this rare disorder. Areas covered: To do this, we carried out a review of the literature using PubMed database of the US National Library of Medicine. We also used data from the American Society of Hematology educational books, textbooks of Hematology and Internal medicine, and information gleaned from international meetings. Expert opinion: Idiosyncratic agranulocytosis remains a potentially serious adverse event due to the frequency of severe sepsis with severe deep tissue infections (e.g., pneumonia), septicemia, and septic shock in approximately two-thirds of all hospitalized patients. In this context, several prognostic factors have been identified that may be helpful when identifying 'susceptible' patients. Old age (>65 years), septicemia or shock, renal failure, and a neutrophil count ≤0.1 × 109/L have been consensually accepted as poor prognostic factors. In our experience, modern management with pre-established procedures, intravenous broad-spectrum antibiotics and hematopoietic growth factors (particularly G-CSF) is likely to improve the prognosis. Thus with appropriate management, the mortality rate is currently between 5 to 10%.

Entities:  

Keywords:  Drug; agranulocytosis; hematopoietic growth factor; idiosyncratic; neutropenia; non-chemotherapy

Mesh:

Year:  2017        PMID: 28879784     DOI: 10.1080/14740338.2017.1376645

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  8 in total

1.  Drug safety surveillance within a strategy for the management of non-chemotherapy drug-induced neutropenia.

Authors:  José Luis Revuelta-Herrero; Raquel García-Sánchez; Javier Anguita-Velasco; Ana de Lorenzo-Pinto; Cristina Ortega-Navarro; María Sanjurjo-Sáez
Journal:  Int J Clin Pharm       Date:  2019-06-29

Review 2.  Agranulocytosis Induced by Vancomycin. Case Report and Literature Review.

Authors:  Horacio di Fonzo; Melina Villegas Gutsch; Augusto Castroagudin; María Victoria Cabrera; Mariano E Mazzei; Darío Rueda
Journal:  Am J Case Rep       Date:  2018-09-03

Review 3.  Antibiotic Hypersensitivity Mechanisms.

Authors:  Jenana H Maker; Cassandra M Stroup; Vanthida Huang; Stephanie F James
Journal:  Pharmacy (Basel)       Date:  2019-08-27

4.  Concurrent severe hepatotoxicity and agranulocytosis induced by Polygonum multiflorum: A case report.

Authors:  You-Lin Shao; Chun-Ming Ma; Jian-Ming Wu; Feng-Cai Guo; Suo-Cai Zhang
Journal:  World J Clin Cases       Date:  2022-09-26       Impact factor: 1.534

5.  Agranulocytosis Induced by Tamoxifen in a Breast Cancer Patient.

Authors:  Hugo Herrscher; Julie Leblanc; Thierry Petit
Journal:  Breast Care (Basel)       Date:  2019-06-20       Impact factor: 2.860

6.  Assessment of Neutrophil Chemotaxis Upon G-CSF Treatment of Healthy Stem Cell Donors and in Allogeneic Transplant Recipients.

Authors:  Anna Thunström Salzer; Maria J Niemiec; Ava Hosseinzadeh; Marios Stylianou; Fredrik Åström; Marc Röhm; Clas Ahlm; Anders Wahlin; David Ermert; Constantin F Urban
Journal:  Front Immunol       Date:  2018-09-11       Impact factor: 7.561

7.  Biochemical and Haematological Predictors of Reduced Neutrophil Granulocyte Count associated with Intravenous Ceftriaxone Treatment.

Authors:  Basant K Puri; Anne Derham; Jean A Monro
Journal:  Rev Recent Clin Trials       Date:  2018

8.  Acetazolamide-Induced Agranulocytosis in a Patient with Pseudotumor Cerebri.

Authors:  Faruk Incecik; Neslihan Ozcan; Duygu G Ozcanyuz; Gulen G Mert
Journal:  Ann Indian Acad Neurol       Date:  2020-12-08       Impact factor: 1.383

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.